Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E54.35 EPS (ttm)2.99 Insider Own0.70% Shs Outstand147.14M Perf Week14.90%
Market Cap23.92B Forward P/E44.50 EPS next Y3.65 Insider Trans-8.94% Shs Float145.15M Perf Month28.31%
Income443.40M PEG4.01 EPS next Q0.81 Inst Own94.80% Short Float3.89% Perf Quarter18.52%
Sales2.37B P/S10.09 EPS this Y30.50% Inst Trans-0.07% Short Ratio3.70 Perf Half Y9.32%
Book/sh15.27 P/B10.65 EPS next Y9.96% ROA11.30% Target Price145.83 Perf Year-7.16%
Cash/sh10.44 P/C15.57 EPS next 5Y13.56% ROE21.80% 52W Range119.37 - 186.88 Perf YTD26.97%
Dividend- P/FCF56.68 EPS past 5Y28.90% ROI16.60% 52W High-13.01% Beta0.77
Dividend %- Quick Ratio3.10 Sales past 5Y19.70% Gross Margin69.90% 52W Low36.19% ATR5.10
Employees4600 Current Ratio3.60 Sales Q/Q10.30% Oper. Margin24.80% RSI (14)78.85 Volatility2.70% 2.61%
OptionableYes Debt/Eq0.47 EPS Q/Q10.40% Profit Margin18.70% Rel Volume0.73 Prev Close162.84
ShortableYes LT Debt/Eq0.46 EarningsJan 31 AMC Payout0.00% Avg Volume1.53M Price162.57
Recom2.70 SMA2019.66% SMA5021.38% SMA2008.61% Volume1,115,230 Change-0.17%
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
Oct-11-16Reiterated Cantor Fitzgerald Hold $165 → $155
Oct-11-16Reiterated Canaccord Genuity Hold $165 → $136
Oct-11-16Downgrade Citigroup Buy → Neutral
Aug-22-16Downgrade CL King Buy → Neutral
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
May-04-16Reiterated Canaccord Genuity Hold $160 → $140
May-03-16Reiterated UBS Buy $210 → $180
May-03-16Reiterated Morgan Stanley Overweight $140 → $130
Apr-19-16Downgrade Cantor Fitzgerald Buy → Hold
Apr-19-16Downgrade BofA/Merrill Buy → Neutral
Feb-04-16Downgrade Canaccord Genuity Buy → Hold $205 → $160
Jan-14-17 04:55PM  Will 2017 Be Illumina's Best Year Yet? at Motley Fool
02:08PM  Illumina Lights It Up at Motley Fool
Jan-13-17 12:46PM  10 Most Interesting Companies In The World at Insider Monkey
Jan-12-17 11:03AM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) & Lead Plaintiff Deadline: February 14, 2017 GlobeNewswire
09:39AM  Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM) at Insider Monkey
09:00AM  Does Illumina Have the Genes for Lasting Growth?
08:22AM  Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution
08:00AM  Illumina, NRGene Collaborate to Accelerate Development of New Molecular Breeding Tools for Cattle to Support Global Food Production Business Wire
Jan-11-17 05:34PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
04:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Illumina, Inc. and Certain Officers ILMN GlobeNewswire
04:03PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Amendments to Articles of Inc. or Byl
01:46PM  Illumina Launches $100 NovaSeq Gene Sequencer at Investopedia
09:30AM  Latest Reports on Egalet and Illumina as the NASDAQ Continues to Hit Record Highs Accesswire
09:00AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Jan-10-17 10:10PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Illumina Inc. (ILMN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit GlobeNewswire +16.60%
07:31PM  Nasdaq Hits Another High As Trump Presser Awaits
07:00PM  Small Caps Soar, Dow Off; Which Tech Stocks Beat Apple In Gains Today?
05:07PM  Why Illumina, Brookdale Senior Living, and Allscripts Healthcare Solutions Jumped Today at Motley Fool
04:31PM  The Hot Stock: Illumina Soars 17% at Barrons.com
04:26PM  Illumina shares spike after firm unveils new gene-sequencing product, upbeat quarterly forecast at CNBC
02:30PM  US STOCKS-Nasdaq hits record high; IBM weighs on Dow
01:07PM  Here's Why Illumina Is Soaring Today at Motley Fool
01:01PM  US STOCKS-Nasdaq hits record, S&P and Dow close in as banks gain
12:01PM  Illumina Stock Upgraded: What You Need to Know at Motley Fool
11:07AM  Illumina Should Dominate in High-Throughput Sequencing
10:47AM  Illumina: Stand and Deliver at Barrons.com
10:12AM  Stocks Mixed; Why Are Illumina, Valeant, Barracuda Soaring?
10:06AM  Illumina's stock soars toward best gain in 5 years after upbeat sales outlook, product upgrade at MarketWatch
09:16AM  Biotech Premarket Movers: ILMN, NSTG, KITE
08:39AM  Illumina CEO: On the path to $100 genome
08:27AM  IBM Watson Partners with Illumina to Advance Cancer Research
07:58AM  Illumina (ILMN) Launches NovaSeq Series for $100 Genome
06:44AM  Illumina upgraded by BofA/Merrill
Jan-09-17 07:10PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
05:35PM  Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases Business Wire
05:30PM  Illumina Introduces the NovaSeq Seriesa New Architecture Designed to Usher in the $100 Genome Business Wire
12:55PM  ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina, Inc. and a Lead Plaintiff Deadline of February 14, 2017 GlobeNewswire
11:19AM  IBM Seals Genomics Partnership With Illumina
09:06AM  Illumina Adds IBM Watson To DNA Test For Cancer Patients at Forbes
09:00AM  IBM and Illumina Partner to Standardize Genomic Data Interpretation PR Newswire
08:45AM  Philips and Illumina join forces to offer integrated genomics solutions for oncology PR Newswire
08:21AM  Why Surging eBay Could Rip Even Higher
07:45AM  Trader rolls for more Illumina upside
Jan-08-17 07:41AM  Why Illumina Corp. Lost One-Third of Its Value in 2016 at Motley Fool
Jan-06-17 05:11PM  The Hot Stock: Illumina Jumps 5.2% at Barrons.com +5.15%
03:17PM  Year-old cancer-testing startup raising a $1B round at bizjournals.com
03:05PM  Illumina Tops the Nasdaq 100 -- and Here's How to Trade It
02:12PM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:21PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Illumina, Inc. ILMN GlobeNewswire
12:08PM  Illumina: Smoke, Mirrors, and GRAIL at Barrons.com
10:55AM  Biotech Investing: 3 Bold Predictions for 2017 at Motley Fool
10:31AM  Illumina, Inc. Value Analysis (NASDAQ:ILMN) : January 6, 2017
09:12AM  Top Analyst Upgrades and Downgrades: Cognizant Tech, Etsy, GoPro, Illumina, Shake Shack, Travelers and More
Jan-05-17 05:07PM  3 Top Growth Stocks for 2017 at Motley Fool
04:05PM  GRAIL Plans to Raise in Excess of $1B in Series B Funding Business Wire
03:41PM  3 Things We Might See From Illumina Next Week at Motley Fool
12:14PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:34AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) and Lead Plaintiff Deadline: February 14, 2017 Accesswire
08:22AM  Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : January 5, 2017
Jan-04-17 10:22AM  Leading Genetic Testing Companies Join Forces to Launch the Coalition for Access to Prenatal Screening PR Newswire
Jan-03-17 10:55AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 ILMN GlobeNewswire
10:33AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) and Lead Plaintiff Deadline: February 14, 2017 Accesswire
09:00AM  Illumina Taps Garret Hampton, One of the Worlds Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit Business Wire
08:02AM  Illumina Fettered With Losses: Can It Bounce Back in 2017?
Jan-02-17 10:37AM  BD Lifesciencess Product Pipeline Could Boost Its Fiscal 2017 Growth
09:07AM  BD Lifesciencess Performance and Core Focus Areas
Dec-30-16 03:28PM  Lead Plaintiff Sought For Class Action Lawsuit Filed Against Illumina, Inc. (ILMN) at Insider Monkey
Dec-29-16 10:06AM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Dec-28-16 10:00PM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Illumina, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
08:45PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
03:33PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 - ILMN Accesswire
Dec-27-16 05:43PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
03:47PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Illumina, Inc. and Certain Officers ILMN GlobeNewswire
03:07PM  3 Precision Medicine Stocks to Buy in January at Motley Fool
03:03PM  ILMN LOSS NOTICE: Rosen Law Firm Reminds Illumina, Inc. Investors of Important Deadline in Class Action ILMN Business Wire
01:47PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Illumina Inc. (ILMN) & Lead Plaintiff Deadline: February 14, 2017 GlobeNewswire
06:30AM  Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference Business Wire
Dec-23-16 05:08PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
03:22PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Illumina, Inc. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire
11:47AM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:30AM  ILMN INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Illumina, Inc. and a Lead Plaintiff Deadline of February 14, 2017 GlobeNewswire
Dec-21-16 08:12PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Tweet Accesswire
06:00PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:31AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Illumina Inc. (ILMN) and Lead Plaintiff Deadline: February 14, 2017 Accesswire
Dec-20-16 06:17PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
05:57PM  Illumina Has Dropped 32% in 2016 -- Is the Bottom Finally in Sight? at Motley Fool
05:10PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Illumina, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline ILMN GlobeNewswire
04:36PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
04:07PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Illumina, Inc. Marketwired
02:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Illumina, Inc. - ILMN PR Newswire
02:02PM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
09:00AM  Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Business Development, Adding Further Clinical and Life Sciences Expertise to its Executive Team Business Wire
Dec-19-16 09:23PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
07:47PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Illumina, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
04:30PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Illumina, Inc. ILMN Business Wire
01:22PM  3 Bets Illumina Is Making for the Long Term at Motley Fool
12:58PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
12:09PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 ILMN GlobeNewswire
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with MolecularMD Corporation for drug-diagnostic co-development with biopharma drug programs; and IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOWMAN A BLAINEDirectorJan 11Option Exercise42.823,000128,46018,704Jan 13 07:05 PM
BOWMAN A BLAINEDirectorJan 11Sale162.893,000488,65815,704Jan 13 07:05 PM
Dadswell CharlesSr VP & General CounselJan 10Sale161.6011618,7468,420Jan 12 09:36 PM
BRADBURY DANIELDirectorJan 04Option Exercise71.0960042,65417,065Jan 06 06:59 PM
BRADBURY DANIELDirectorJan 04Sale135.0160081,00816,465Jan 06 06:59 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 15Sale126.162,000252,32031,040Dec 19 08:08 PM
BRADBURY DANIELDirectorDec 12Option Exercise71.0960042,65417,065Dec 14 08:09 PM
BRADBURY DANIELDirectorDec 12Sale123.4260074,05416,465Dec 14 08:09 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 08Sale121.633,000364,89052,988Dec 09 04:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale133.303,000399,90051,492Dec 05 06:41 PM
BRADBURY DANIELDirectorNov 14Option Exercise71.0960042,65417,065Nov 15 06:14 PM
BRADBURY DANIELDirectorNov 14Sale136.3460081,80316,465Nov 15 06:14 PM
BRADBURY DANIELDirectorOct 07Option Exercise71.0960042,65417,065Oct 11 08:35 PM
BRADBURY DANIELDirectorOct 07Sale184.36600110,61316,465Oct 11 08:35 PM
Dadswell CharlesSr VP & General CounselOct 04Sale182.3811621,15639,900Oct 06 05:32 PM
EPSTEIN ROBERT SDirectorSep 20Sale174.2930052,2876,924Sep 21 06:56 PM
Stapley MarcEVP & Chief Administrative OfcSep 15Sale172.871,270219,54332,746Sep 16 08:07 PM
BRADBURY DANIELDirectorSep 14Option Exercise71.0960042,65417,065Sep 16 07:58 PM
BRADBURY DANIELDirectorSep 14Sale171.25600102,74816,465Sep 16 07:58 PM
Dadswell CharlesSr VP & General CounselSep 06Sale168.0111619,48940,016Sep 08 07:58 PM
FLATLEY JAY TDirectorAug 23Option Exercise36.3020,000726,000508,061Aug 25 08:43 PM
FLATLEY JAY TDirectorAug 23Sale172.9920,0003,459,877488,061Aug 25 08:43 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 24 07:52 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 23 08:19 PM
BRADBURY DANIELDirectorAug 17Option Exercise71.0960042,65417,065Aug 18 08:31 PM
BRADBURY DANIELDirectorAug 17Sale168.42600101,05316,465Aug 18 08:31 PM
FLATLEY JAY TDirectorAug 15Option Exercise36.3010,000363,000498,061Aug 16 06:56 PM
FLATLEY JAY TDirectorAug 15Sale170.0010,0001,700,000488,061Aug 16 06:56 PM
WHITFIELD ROY ADirectorAug 12Option Exercise42.824,000171,2806,853Aug 15 06:03 PM
WHITFIELD ROY ADirectorAug 12Sale167.224,000668,8802,853Aug 15 06:03 PM
FLATLEY JAY TDirectorAug 09Option Exercise36.3010,000363,000498,061Aug 10 09:40 PM
FLATLEY JAY TDirectorAug 09Sale165.9710,0001,659,650488,061Aug 10 09:40 PM
Dadswell CharlesSr VP & General CounselAug 04Sale164.6311619,09740,132Aug 08 06:36 PM
FLATLEY JAY TDirectorAug 01Option Exercise36.3010,000363,000498,061Aug 02 07:27 PM
FLATLEY JAY TDirectorAug 01Sale170.0010,0001,700,000488,061Aug 02 07:27 PM
Dadswell CharlesSr VP & General CounselJul 27Sale155.008,6321,337,96040,248Jul 28 07:44 PM
FLATLEY JAY TDirectorJul 26Option Exercise36.3010,000363,000498,061Jul 28 07:39 PM
FLATLEY JAY TDirectorJul 26Sale150.0010,0001,500,000488,061Jul 28 07:39 PM
EPSTEIN ROBERT SDirectorJul 20Sale150.0030045,0007,524Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Option Exercise36.3010,000363,000498,061Jul 20 08:06 PM
EPSTEIN ROBERT SDirectorJul 18Sale150.00900135,0007,824Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Sale150.0010,0001,500,010488,061Jul 20 08:06 PM
BOWMAN A BLAINEDirectorJul 14Option Exercise42.825,000214,10020,704Jul 15 06:53 PM
BOWMAN A BLAINEDirectorJul 14Sale147.145,000735,70515,704Jul 15 06:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJul 11Sale141.89716101,59318,976Jul 12 07:47 PM
BOWMAN A BLAINEDirectorJun 16Option Exercise42.825,000214,10020,704Jun 17 07:53 PM
BOWMAN A BLAINEDirectorJun 16Sale135.085,000675,38815,704Jun 17 07:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJun 15Sale137.902,141295,24219,692Jun 15 06:47 PM
WHITFIELD ROY ADirectorJun 13Option Exercise42.822,00085,6406,653Jun 15 06:34 PM
WHITFIELD ROY ADirectorJun 13Sale140.443,800533,6722,853Jun 15 06:34 PM
EASTHAM KARINDirectorJun 01Option Exercise36.295,000181,45017,424Jun 03 07:28 PM
EASTHAM KARINDirectorJun 01Sale145.355,000726,75012,424Jun 03 07:28 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 25Sale144.732,141309,86721,833May 26 07:44 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 17Sale140.842,141301,53223,974May 19 06:56 PM
BOWMAN A BLAINEDirectorMay 12Option Exercise36.295,000181,45018,615May 13 06:03 PM
BOWMAN A BLAINEDirectorMay 12Sale137.115,000685,53513,615May 13 06:03 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 27Sale138.462,141296,44626,115Apr 28 06:34 PM
Bianchi Paul LSr. VP, Human ResourcesApr 18Sale175.001,884329,70065,660Apr 20 05:33 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 18Sale176.012,141376,83528,256Apr 20 05:57 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Option Exercise37.0412,500463,00042,897Apr 14 06:43 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Sale175.0012,5002,187,50030,397Apr 14 06:43 PM
WHITFIELD ROY ADirectorApr 12Option Exercise42.824,000171,2805,800Apr 14 06:21 PM
FLATLEY JAY TChief Executive OfficerApr 12Option Exercise36.3020,000726,000508,061Apr 14 06:42 PM
FLATLEY JAY TChief Executive OfficerApr 12Sale170.0520,0003,401,014488,061Apr 14 06:42 PM
WHITFIELD ROY ADirectorApr 12Sale170.004,000680,0001,800Apr 14 06:21 PM
WALT DAVID RDirectorApr 07Option Exercise13.304,00053,200635,840Apr 11 05:58 PM
WALT DAVID RDirectorApr 07Sale168.904,000675,596631,840Apr 11 05:58 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 05Sale166.072,141355,54630,397Apr 06 05:29 PM
Dadswell CharlesSr VP & General CounselApr 04Sale167.818,3821,406,60449,859Apr 06 05:19 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 23Sale155.052,141331,95732,538Mar 23 05:41 PM
FLATLEY JAY TChief Executive OfficerMar 22Option Exercise36.3010,000363,000498,061Mar 23 05:39 PM
FLATLEY JAY TChief Executive OfficerMar 22Sale154.1810,0001,541,759488,061Mar 23 05:39 PM
BRADBURY DANIELDirectorMar 21Option Exercise44.511,20053,41215,576Mar 22 02:51 PM
BRADBURY DANIELDirectorMar 21Sale155.631,200186,75614,376Mar 22 02:51 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 21Sale154.254,520697,21030,020Mar 22 02:48 PM
BOWMAN A BLAINEDirectorMar 17Option Exercise36.295,000181,45018,615Mar 18 08:49 PM
BOWMAN A BLAINEDirectorMar 17Sale145.245,000726,19213,615Mar 18 08:49 PM
WALT DAVID RDirectorMar 15Option Exercise13.304,00053,200635,840Mar 16 09:16 PM
WALT DAVID RDirectorMar 15Sale149.994,000599,961631,840Mar 16 09:16 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 14Sale155.915,892918,61834,679Mar 15 07:42 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 09Sale150.32871130,92955,189Mar 11 11:43 AM
FLATLEY JAY TChief Executive OfficerMar 08Option Exercise36.3010,000363,000500,915Mar 09 06:45 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 08Sale156.094,516704,90256,060Mar 09 06:52 PM
FLATLEY JAY TChief Executive OfficerMar 08Sale154.4910,0001,544,864490,915Mar 09 06:45 PM
Dadswell CharlesSr VP & General CounselMar 08Sale155.648,2661,286,51758,241Mar 09 06:38 PM
Dadswell CharlesSr VP & General CounselMar 07Sale155.0011617,98066,507Mar 09 06:38 PM
Stapley MarcEVP & Chief Administrative OfcMar 03Option Exercise0.0024,000040,801Mar 07 08:11 PM
FLATLEY JAY TChief Executive OfficerMar 03Option Exercise0.0083,8300514,614Mar 07 08:09 PM
deSouza Francis APresidentMar 03Option Exercise0.0049,2190118,880Mar 07 08:07 PM
Ronaghi MostafaSr VP & CTOMar 03Option Exercise0.0020,063062,763Mar 07 08:05 PM
ORPIN TRISTANEVP Clinical GenomicsMar 03Option Exercise0.0024,0000125,797Mar 07 08:02 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 03Option Exercise0.0020,063040,866Mar 07 08:00 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 03Option Exercise0.0024,000047,536Mar 07 07:58 PM
Dadswell CharlesSr VP & General CounselMar 03Option Exercise0.0033,750075,325Mar 07 07:56 PM
Bouchard MichelChief Accounting OfficerMar 03Option Exercise0.008,250023,746Mar 07 08:14 PM
FLATLEY JAY TChief Executive OfficerFeb 23Option Exercise36.3010,000363,000440,784Feb 25 07:05 PM
FLATLEY JAY TChief Executive OfficerFeb 23Sale152.4910,0001,524,850430,784Feb 25 07:05 PM
BRADBURY DANIELDirectorFeb 17Option Exercise44.511,70075,66716,076Feb 19 11:27 AM
BRADBURY DANIELDirectorFeb 17Sale154.741,700263,05114,376Feb 19 11:27 AM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 01Sale156.731,108173,65746,476Feb 03 06:58 PM